Marc Rogers (Metrion Director and CSO) takes part in a collaborative webinar with Nanion Technologies entitled “Validation and optimization of automated patch clamp voltage-gated Ca2+ channel assays”.

Marc Rogers (Metrion Director and CSO) outlines the benefits of targeting ion channels for pain and some of the hurdles in developing successful ion channel modulators.

Marc Rogers (Metrion Director and CSO) and Nick Tate (Company Secretary and Finance Director) present at the 8th February 2018 SR Live event during Metrion’s 2018 Syndicate Room finance round.

Presentation by Marc Rogers (Metrion CSO) at the June 2016 Sophion Ion Channel Modulation Symposium, Clare College, Cambridge (UK). CiPA update: in vitro cardiac ion channels screens, in silico models and stem cells iPS cardiomyocyte assays for pro-arrhythmia risk prediction.

Presentation by Marc Rogers (Metrion CSO) at the September 2015 Safety Pharmacological Society, Prague. Using high quality HTS automated patch clamp data from human cardiac ion channels and in silico action potential modelling to cost-effectively predict QP prolongation and arrhythmia risk for CiPA.